My prediction of the proxy votes outcome is as follow:

- approval for R/S ratio = 1/15, then total # outstanding shares will be around 4.65M shares @ $5.5/share.

- announcement of a secondary offering for 20M new shares @ $5/share to receive $100M, the additional money needed for keeping the company alive until 2021 Q1.

It's funny that bagholders is trying to spin that 1.7M shares purchased by Renaissance (filed on 2/12/19)
https://fintel.io/soh/us/adxs/renaissance-technologies-llc

But they selected to ignore the facts that other institutions dumping similar amount of shares around the same time.

- first, Adage dumped 1.5M share (filed on 2/13)
https://fintel.io/soh/us/adxs/adage-capital-partners-gp-llc

- CVI reduced nearly 15% of their holding (filed on 2/14)
https://fintel.io/soh/us/adxs/cvi-investments


Commplete report on the transactions:
https://fintel.io/so/us/adxs

BTW, Amgen stilll has 3M shares to dump after terminating partnership with this crappy, scam Adxs

Advaxis' Cervical Cancer Study Placed On Partial Clinical Hold
Shanthi Rexaline , Benzinga Staff Writer FOLLOW
January 24, 2019 7:45am
Advaxis, Inc.
ADXS said the FDA has notified it regarding its Phase 3 study that is evaluating axalimogene filolisbac in high risk advanced cervical cancer being put on partial clinical hold. The company said the partial hold is related to requests for additional information regarding certain AXAL chemistry, manufacturing and controls matter.

The FDA did not raise any safety issues and the currently enrolled patients will continue to receive treatment, as per the trial protocol, the company said. However, the company has been barred from enrolling new patients in AIM2CERV until the resolution of the partial hold.

https://www.benzinga.com/general/biotech/19/01/13028919/the-daily-biotech-pulse-partial-clinical-hold-on-advaxis-cervical-can

I guess this will further delay the clinical and more cash burn due to managements incompetency.

Without partnership announcement, this penny adxs should be traded under ¢10/share (yes, under ten cents/share)

your investment at this state your investment is like you're in hospice care and you're still thinking that it aint over yet friendo?

A classic bagholder excuse.

You're right; this garbage ADXS is no longer a biotech, that's why it should drop like general market out there given ^DJI in red by 400pts.

Biotech indexes: IBB & XBI are all green today:
https://finance.yahoo.com/quote/XBI?p=XBI
https://finance.yahoo.com/quote/IBB?p=IBB

There won't be any Sushi nor Sapporo beer, but
there will be some Nature’s Variety available for free.... kkk

Don't be too excited about the 0.05 cent gain today.
You'd better take a look at the small volume today with only 540K share (vs. the typical 863K share/day), so it's obvious someone trying to move the price up prior to their dumping/selling shares in the next couple weeks. Take a look at the following link; Vanguard Group already dumped their entire holding in Q3:
https://fintel.io/soh/us/adxs/vanguard-group

I think it will be Blackrock dumpping next and then Adage
https://fintel.io/soh/us/adxs/blackrock
https://fintel.io/soh/us/adxs/adage-capital-partners-gp-llc

Don't waste any more of your money on this crappy ADXS.
Lm-LLO-Based Immunotherapies clinical results are just not that impressive, but also unsafe and the technology is outdated; please simply google for these terms and you will find most of the articles were dated years ago.
Amgen made a mistake and they lost millions on this just like many other institutions...

I'm pretty sure this garbage will trade in the $0.20s -> $0.30/share range in a few weeks.

Please forward this link to your son; "deferred revenue" is always a part of liability/debts in the balance sheets
https://www.investopedia.com/terms/d/deferredrevenue.asp

Being listed as "deferred revenue", because Advaxis's existing cash includes the money someone had paid Advaxis earlier for the service/products they haven't received. Therefore, in the event Advaxis liquidated, those cash will be returned. Because of this "Deferred revenue" is listed as a part of the liability/debts.

It's from the most recent 10-Q:
https://www.sec.gov/Archives/edgar/data/1100397/000149315218013055/form10-q.htm

Re: post #144497679

100% agree with you on the continuation of funding AIM2CERV trial will likely cause a new selloff.
However, winding down of AIM2CERV, a clinical trial with over 450 participants across over 115 locations, will also come with a cost . Because ADXS can't simply have everything shutdown and leave, but they must assist existing patients with the transition out of AIM2CERV and closing out the the clinical locations. This will come with a cost could be the same as the cost for setting up the clinical locations and recruiting patients, and will definitely cause another sell-off due to this amount of cash burn.

As of 07/31/18, Advaxis has $40M cash + $13M value of property/equipment and intangible assets. But they has $28M in debt and their cash burn in the last 3 months should be around $12M to $14M. So including the cost for winding down AIM2CERV ADXS will probably have around $20M cash left. With this they definitely need for another round of second offering to be announced very soon.
Given the total 70M outstanding shares, small amount of cash ($20M+$13M -$28M) = $5M, ADXS currently has a cash value of 5/70 = $0.07/share. With this ADXS share price should be traded under $0.25/share.

It's just unbelievable that people selling their ARDX shares today, because of Synergy (SGYP) filing bankruptcy. I wonder if they really looked at the the10-Qs before selling their shares?
If you take a look at Synergy's latest 10-Q (link below), they're loaded with debts @ $161M, but their total asset valued only $90M. They tried to renegotiate the loan terms, but failed that's why filing bankruptcy is necessary.
Synergy's latest 10-Q can be viewed here:
https://www.sec.gov/ix?doc=/Archives/edgar/data/1347613/000134761318000027/sgyp-20180630.htm

But for Ardelyx (ARDX), currently has over $228M in total asset (with $221M current asset), but the total debt/liabilities is on $65M. In case ARDX decided to pay off all the debts, they still have plenty of cash with over $163M left, so why selling today??? Also, Synergy out of business means one less competitor and should interpreted as for a positive news for Ardelyx, right?

Ardelyx's latest 10-Q can be viewed via the following link:
https://www.sec.gov/Archives/edgar/data/1437402/000155837018006606/ardx-20180630x10q.htm

Today 30% drop in share price is expected ... and this turd is going to trade under $0.50/share in December!

How do you come up the idea that "EDGE burning through cash." ???

Did you know that they've reduce 2/3 of workforce and with on 13 employees left? How much cash they'll burn per quarter with 13 employees?
"Edge continues to conduct a review of strategic alternatives focused on maximizing stockholder value. Edge has largely completed the process of streamlining its operations, including reducing its headcount from 37 to 13 employees by June 30, 2018."

The new release (or update) yesterday was significant; data collected from 266 patient is much better than the data reported from 210 patients and DMC recommendation would be different if it's based on the latest result.
EDGE will provide the final update of all 283 patients later this year. If the final data is consistent with the latest results, then I guess they have the option for continuing EG-1962 development beside merge/acquisition

Take a look at the following wiki page and understand about the roles of DMC in clinical trials then you will see that everything EDGE had done was correct and the lawsuits are without merit.
https://en.wikipedia.org/wiki/Data_monitoring_committee

It would be a big legsal issue if they decided to continue the clinical trials and ignored those recommendations from DMC

Make sure you're looking at your investment account balance while laughing...

I guess the following are fake-news to you:

"New Study Shows Listeria Vaccine For Cervical Cancer Found Safe"
http://ir.advaxis.com/press-release/clinical-data-updates/new-study-shows-listeria-vaccine-cervical-cancer-found-safe

Trials of Advaxis’ cervical cancer drug on hold after patient death"
https://www.pharmaceutical-technology.com/news/advaxis-trial-death/

Of course Advaxis claimed this safety since 2007:
"New Study Shows Listeria Vaccine For Cervical Cancer Found Safe"
http://ir.advaxis.com/press-release/clinical-data-updates/new-study-shows-listeria-vaccine-cervical-cancer-found-safe

And then this:
"Trials of Advaxis’ cervical cancer drug on hold after patient death"
https://www.pharmaceutical-technology.com/news/advaxis-trial-death/

Between CDC, FDA and this crappy company led by an attorney (the least trusted profession), who would you believe in >

ADXS-NEO will never start for they don't have enough participants.
https://clinicaltrials.gov/ct2/show/NCT03265080?term=advaxis&rank=1

With an estimated 1,600 people get listeriosis each year and about 260 (or 16%) die from the infection (actual data from CDC). Unless you're about to die, no one would want to risk their life from getting infected with listeria. And for those about to die patients, they'll eventually die during the clinical trial, and once again FDA will halt the trial just like they did in the AXAL trial. It's as simple as that unfortunately someone with a PhD degree couldn't get it :(

Advaxis keeps on delaying and delaying this NEO trial... Why???
It's probably because no one would want to risk their life in participating this NEO trial after the fact that a patient died in one of Advaxis earlier clinical trials

No way that Hail-Mary filing would be approved.
This turd is heading to $1/share by August and $0.50/share by December

I posted the impossible just for fun.
After witnessing all crappies going on at Advaxis in 2017, Denner dumped all his shares for loss rather than adding shares and taking over leadership like he did at Ariad. It's obvious that Denner no longer believed in LM nor any value for continuing his investment in this company.

I will move ALL my money into Advaxis upon hearing the news Alex Denner replacing David Sidransky as COB.

Anyone notice this?
https://www.linkedin.com/in/david-sidransky-0095253/

I think the problem with Advaxis is having David Sidransky as COB. This guy is all over different companies: COB at Advaxis, Champion Oncology, Tamir Biotech, and also as active board member at Galmed, Rosetta and Orgenesis. It's not only issue with conflicted interests, but with many involvements no way the guy could focus and come up with the best decisions for Adavaxis shareholders. As an active member of the board at Rosetta, it's probably Sidransky (not Lambardo) had hand-picked Ken Berlin as Advaxis new CEO.

AF was wrong on ARIA, but he's correct on EXEL, which eventually reached almost $30 while ARIA sold @$24.

Regarding to ADXS, it's crappy company (that's AF ignore) and that's why only those lawyers (BTW, the most untrusted professional) are interested in running. and those guys are thirsty for your money. Look at how much money you guys had given DOC? Kenny boy is going to the same here.

You're obviously sharing the same mentality like the majority of failed investors out there regarding to AF.

This isn't from me:
"Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. A veteran journalist, Adam was most recently Senior Columnist at TheStreet, where he wrote about biotech and drug stocks. Adam lives near Boston with his wife, two kids and Bo, an insanely cute boxer/mutt."

After three quarters at helm, what Tony had done except burning cash quarter by quarter? So, he had to do something to show the world he had accomplished something rather than simply taking 9 months for hiring lousy CEO/CMO, right? That's why he decided doing that Hail-Mary filing.
So good luck to you with that 1% chance of approval.

BTW, it's not me calling that filing a Hail-Mary. It's from AF and some reputable bio-tech investment specialists out there.

Ask yourself this question: Why Tony and BOD didn't seek out those good name (proven) former CEO like Paris Panayiotopoulos to lead the comapny, or added successfully biotech investor like Alex Denner to the BOD ?
The answer is very simple; Advaxis LM-based immunotherapy is unimpressive, a complete waste of time/resource and no reputable CEO, nor successful investor want to touch this crappy company.

This crappy stock is heading $0.20/share in the upcoming months.
Mark this post!

I'm pretty sure that Kenny is going to sell this beech @ $50/share in April/2019 after doing 1/250 reverse split.

TL and the BOD at Advaxis burn three quarters of cash only to find these two CEO/CMO?
This is definitely DOC version 2.0:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140254796

100% TRUE!!!
What's a crappy company that's why none of the good names in biopharma industry is interested in this company, and they had to hire the two crappy CEO/CMO.

Congrats to ADXS sharesholders for once again you're getting another former-lawyer-became-CEO. And just like the old Dan O'Connor, the new guy is given a couple months to drive ADXS share price down to $0.20/share, announce a 1/125 reverse split (to make it become $25/share), and then do another 2nd offering by issuing 10 million new shares @ $20/share to collect $200M cash to ensure that Advaxis continues the best place to work in NJ.
I'm so glad that I've traded ALL my ADXS for EDGE shares last week.

we're going to see HOD at the close and you're going to disappear from this messageboard... :)

Yes, 100% agree with you EDGE is way undervalued.
Trade ALL my ADXS shares (20K) for EDGE this morning.
Holding 27K shares @ $1.28/shr and looking for at least 100% gain in EDGE.

Hold my shares for BO tommorow, this Friday or the up coming weeks...
Let's sell this beech @ $50, Tony

I'm a newbie here and I bought 20K last week at $1.55.
Should I continue to hold the shares for BO or selling today for quick gain of $4200?
Thanks